RGX-202

Names

[ CAS No. ]:
353-09-3

[ Name ]:
RGX-202

[Synonym ]:
EINECS 206-530-0
β-Alanine, N-(aminoiminomethyl)-
3-(diaminomethylideneamino)propanoic acid
n-carbamimidoyl-|A-alanine
beta-Guanidinopropionic acid
3-Guanidinopropanoate
3-carbamimidamidopropanoic acid
N-Carbamimidoyl-β-alanine
N-(Aminomethyl)-β-alanine
MFCD00045939
Guanidinopropionic acid
3-Guanidinopropionic Acid
β-Guanidinopropionic acid
b-Guanidinopropionate
3-Guanidinopropanoic acid
3-guanidinepropionic acid

Biological Activity

[Description]:

RGX-202 is an oral small-molecule SLC6A8 transporter inhibitor. RGX-202 robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. RGX-202 can be used for the research of cancer[1].

[Related Catalog]:

Research Areas >> Cancer

[Target]

Human Endogenous Metabolite

[In Vitro]

RGX-202 (10 μM; 96 hours) reduces cell growth, and reveals a nearly complete depletion of phosphocreatine (>99%), greater than 79% reduction in cellular creatine and a substantial (46%) reduction in intracellular ATP levels relative to control cells in hypoxia[1].

[In Vivo]

RGX-202 (800 mg/kg; p.o. for 35 days) reduces UN-KPC-961 pancreatic tumoral creatine levels in B6129SF1/J mice[1]. RGX-202 (approximately 650 mg/kg; i.p. daily for 14 days) treatment reduces Lvm3b cells liver metastatic colonization by eightfold in NOD-SCID mice[1]. Animal Model: UN-KPC-961 pancreatic tumor-bearing B6129SF1/J mice[1] Dosage: 800 mg/kg Administration: p.o. for 35 days Result: Suppressed tumoral d3-creatine import by 50% at 800 mg/kg. Animal Model: 6- to 9-week-old C57BL/6J male wild-type mice[1] Dosage: 100, 250, 500 mg/KG in sterile 0.9% NaCl Administration: p.o. for 35 days Result: Inhibited tissue uptake of d3-creatine in a dose-dependent manner by up to 75% at 500 mg/kg.

[References]

[1]. Kurth I, et al. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 Oct 8;7(41):eabi7511.

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
299.1±42.0 °C at 760 mmHg

[ Melting Point ]:
222 °C (dec.)(lit.)

[ Molecular Formula ]:
C₄H₉N₃O₂

[ Molecular Weight ]:
131.133

[ Flash Point ]:
134.7±27.9 °C

[ Exact Mass ]:
131.069473

[ PSA ]:
99.20000

[ LogP ]:
-1.68

[ Vapour Pressure ]:
0.0±1.3 mmHg at 25°C

[ Index of Refraction ]:
1.575

[ Storage condition ]:
−20°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi:Irritant;

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ RTECS ]:
AY3157500

[ HS Code ]:
2925290090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2925290090

[ Summary ]:
2925290090 other imines and their derivatives; salts thereof。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:30.0%

Articles

Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4.

Eur. J. Pharmacol. 519(1-2) , 43-7, (2005)

Searching for potent and subtype selective parent structures of the murine gamma-aminobutyric acid (GABA) transporter subtypes mGAT3 and mGAT4 a series of amino acids was characterised in a uniform [3...

Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).

Bioorg. Med. Chem. 19 , 6409-18, (2011)

The proton-coupled amino acid transporter hPAT1 has recently gained much interest due to its ability to transport small drugs thereby allowing their oral administration. A three-dimensional quantitati...

Accumulation of methylguanidine and changes in guanidino compound levels in plasma, urine, and kidneys of furosemide-treated rats.

Metab. Clin. Exp. 57(6) , 802-10, (2008)

Antidiuresis and renal diseases alter the levels of guanidino compounds (GCs) in various tissues. Therefore, we hypothesized that diuresis could also disturb GC metabolism, storage, and elimination. I...